Jaya Biosciences

Executive Summary

Jaya Biosciences is a privately held, pre-clinical stage biotechnology company headquartered in San Diego, California, focused on developing central nervous system (CNS)-directed gene therapies for genetically defined neurodegenerative diseases. The company's pipeline targets Alzheimer's disease, Parkinson's disease, and frontotemporal dementia, addressing significant unmet medical needs in these progressive and debilitating conditions. Leveraging proprietary gene therapy platforms, Jaya aims to deliver therapeutic genes directly to affected neurons, potentially modifying disease progression rather than merely treating symptoms. As a pre-clinical entity, Jaya has not yet advanced any programs into human clinical trials, but its approach aligns with the growing interest in genetic medicine for CNS disorders. The company operates in a competitive landscape with several other gene therapy developers, but its focus on specific genetic subtypes may provide differentiation. With no disclosed funding rounds or valuation, Jaya remains an early-stage opportunity that will require significant capital and successful preclinical validation to progress toward the clinic.

Upcoming Catalysts (preview)

• Q2 2027IND-enabling studies completion for lead program60% success
• Q4 2026Series A or B financing round40% success
• Q3 2026Preclinical efficacy data publication in peer-reviewed journal50% success